Government plans to sell Lloyds shares to the public will mean financial gains for a lucky few but political insurance for the bank.
The iron-ore market is discovering why the archenemy of high commodity prices is, well, high commodity prices.
The bubble’s deflation shows China’s reputation for omnipotence in economic matters is hardly unassailable.
Noble Group has been busy buying back its beleaguered stock. That risks weakening the more important fight: defending its credit.
German salt and fertilizer company K+S AG rejected a takeover approach worth $8.75 billion by rival Potash Corp. of Saskatchewan, saying the proposal undervalued the company.
Activism-defense specialist William Anderson is leaving Goldman Sachs for Evercore Partners, according to people familiar with the matter.
U.S. regulators are sounding the alarm about banks’ exposure to oil and gas producers, a move that could limit their ability to lend to companies battered by a yearlong slump in prices.
BP agreed to pay $18.7 billion over 18 years to settle all federal and state claims arising from 2010’s Deepwater Horizon oil spill, including the biggest pollution penalty in U.S. history.
Vertex’s cystic-fibrosis drug Orkambi, which treats the most common mutation of the disease, received U.S. regulatory approval on Thursday.
Regulators are likely to take action before summer’s end against Fiat Chrysler over recall lapses involving older Jeeps tied to rear-end crashes and millions of other vehicles, the U.S. auto-safety chief said.